Developer of second-phase tumor drugs Starton(STA.US) sets IPO pricing at $5-7 per share, with fundraising scale lowered 25% to $30 million.

According to cnstock.com, on Tuesday, the second-stage oncology drug developer Starton Holdings lowered the planned transaction size for its upcoming initial public offering (IPO). The company currently plans to issue 5 million shares of stock at a price of $5-7 per share, raising $30 million, a 25% decrease from its previous planned fundraising size - the company previously planned to issue 6.7 million shares at the same price range. The company plans to list on the Nasdaq under the ticker symbol "STA".